Global Injectable Suspensions Market
Global Injectable Suspensions Market

Injectable Suspensions Comprehensive Study by End Users (Hospitals & Clinics, Home Care Settings, Other Facilities of Use), Distribution Channel (Hospitals, Retail Pharmacy Stores), Therapeutic (Auto-immune diseases, Hormonal Disorders, Orphan Diseases, Oncology, Other) Players and Region - Global Market Outlook to 2026

Injectable Suspensions Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2022 Edition 205 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Injectable Suspensions?
Injectable suspensions have a stable dispersed thing and are heterogonous systems. They can solely be administered through subcutaneous or intramuscular techniques. Vasoocclusion might also show up after intravenous injection. Parenteral suspensions are additionally acknowledged as injectable suspensions. Most parenteral suspensions are designed for intramuscular or subcutaneous administration. Triamcinolone Acetonide Injectable suspension and insulin zinc suspension, are example, to designed to be administered intramuscularly and subcutaneously, respectively.

The market study is broken down and major geographies with country level break-up.

The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Analysts at AMA Research estimates that Vendors from United States will contribute to the maximum growth of Global Injectable Suspensions market throughout the predicted period. Established and emerging Vendors should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

AstraZeneca (United Kingdom), Teva (Israel), Mylan (United States), Sandoz (Switzerland), Cosmo Pharmaceuticals (Ireland), Salix (United States), Chiesi Farmaceutici (Italy), Orion Corporation (Finland), Cipla (India) and Synmosa Biopharma (Taiwan) are some of the key players that are part of study coverage. Additionally, the Vendors which are also part of the research coverage are Lunan Better Pharma (United States) and Shanghai Sine Promod (China).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Injectable Suspensions market by Type, Application and Region.

On the basis of geography, the market of Injectable Suspensions has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Users, the sub-segment i.e. Hospitals & Clinics will boost the Injectable Suspensions market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospitals will boost the Injectable Suspensions market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Therapeutic, the sub-segment i.e. Auto-immune diseases will boost the Injectable Suspensions market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

In 2021, Cosmo Pharmaceuticals announced today that Cassiopea SpA (SIX: SKIN), a company in which it holds 46.56% of the ordinary shares, has signed license and supply agreements with Sun Pharmaceutical Industries Ltd.


Market Trend
  • Adopting collaboration and acquisition strategies to develop and commercialize

Market Drivers
  • Increasing use in pharmaceutical research activities

Opportunities
  • Growing use of injectable contraceptives

Restraints
  • Product recalls in the injectable suspensions technology market

Challenges
  • Lack of availability of skilled analyst


Key Target Audience
Injectable suspensions Manufacturers, Injectable suspensions Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Frequently Asked Questions (FAQ):

1. What all players are profiled in the study?
The standard version of the report profiles players such as AstraZeneca (United Kingdom), Teva (Israel), Mylan (United States), Sandoz (Switzerland), Cosmo Pharmaceuticals (Ireland), Salix (United States), Chiesi Farmaceutici (Italy), Orion Corporation (Finland), Cipla (India) and Synmosa Biopharma (Taiwan) etc.

2. Can we have customized study for Injectable Suspensions Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. What would be the Market Size of Injectable Suspensions Market by 2026?
Analysts at AMA estimates Injectable Suspensions Market to reach USD Million by 2026.
Report Objectives / Segmentation Covered
By End Users
  • Hospitals & Clinics
  • Home Care Settings
  • Other Facilities of Use

By Distribution Channel
  • Hospitals
  • Retail Pharmacy Stores

By Therapeutic
  • Auto-immune diseases
  • Hormonal Disorders
  • Orphan Diseases
  • Oncology
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing use in pharmaceutical research activities
    • 3.3. Market Challenges
      • 3.3.1. Lack of availability of skilled analyst
    • 3.4. Market Trends
      • 3.4.1. Adopting collaboration and acquisition strategies to develop and commercialize
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Injectable Suspensions, by End Users, Distribution Channel, Therapeutic and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Injectable Suspensions (Value)
      • 5.2.1. Global Injectable Suspensions by: End Users (Value)
        • 5.2.1.1. Hospitals & Clinics
        • 5.2.1.2. Home Care Settings
        • 5.2.1.3. Other Facilities of Use
      • 5.2.2. Global Injectable Suspensions by: Distribution Channel (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Retail Pharmacy Stores
      • 5.2.3. Global Injectable Suspensions by: Therapeutic (Value)
        • 5.2.3.1. Auto-immune diseases
        • 5.2.3.2. Hormonal Disorders
        • 5.2.3.3. Orphan Diseases
        • 5.2.3.4. Oncology
        • 5.2.3.5. Other
      • 5.2.4. Global Injectable Suspensions Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Injectable Suspensions (Volume)
      • 5.3.1. Global Injectable Suspensions by: End Users (Volume)
        • 5.3.1.1. Hospitals & Clinics
        • 5.3.1.2. Home Care Settings
        • 5.3.1.3. Other Facilities of Use
      • 5.3.2. Global Injectable Suspensions by: Distribution Channel (Volume)
        • 5.3.2.1. Hospitals
        • 5.3.2.2. Retail Pharmacy Stores
      • 5.3.3. Global Injectable Suspensions by: Therapeutic (Volume)
        • 5.3.3.1. Auto-immune diseases
        • 5.3.3.2. Hormonal Disorders
        • 5.3.3.3. Orphan Diseases
        • 5.3.3.4. Oncology
        • 5.3.3.5. Other
      • 5.3.4. Global Injectable Suspensions Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Injectable Suspensions (Price)
  • 6. Injectable Suspensions: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Teva (Israel)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Mylan (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sandoz (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Cosmo Pharmaceuticals (Ireland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Salix (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Chiesi Farmaceutici (Italy)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Orion Corporation (Finland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Cipla (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Synmosa Biopharma (Taiwan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Injectable Suspensions Sale, by End Users, Distribution Channel, Therapeutic and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Injectable Suspensions (Value)
      • 7.2.1. Global Injectable Suspensions by: End Users (Value)
        • 7.2.1.1. Hospitals & Clinics
        • 7.2.1.2. Home Care Settings
        • 7.2.1.3. Other Facilities of Use
      • 7.2.2. Global Injectable Suspensions by: Distribution Channel (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Retail Pharmacy Stores
      • 7.2.3. Global Injectable Suspensions by: Therapeutic (Value)
        • 7.2.3.1. Auto-immune diseases
        • 7.2.3.2. Hormonal Disorders
        • 7.2.3.3. Orphan Diseases
        • 7.2.3.4. Oncology
        • 7.2.3.5. Other
      • 7.2.4. Global Injectable Suspensions Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Injectable Suspensions (Volume)
      • 7.3.1. Global Injectable Suspensions by: End Users (Volume)
        • 7.3.1.1. Hospitals & Clinics
        • 7.3.1.2. Home Care Settings
        • 7.3.1.3. Other Facilities of Use
      • 7.3.2. Global Injectable Suspensions by: Distribution Channel (Volume)
        • 7.3.2.1. Hospitals
        • 7.3.2.2. Retail Pharmacy Stores
      • 7.3.3. Global Injectable Suspensions by: Therapeutic (Volume)
        • 7.3.3.1. Auto-immune diseases
        • 7.3.3.2. Hormonal Disorders
        • 7.3.3.3. Orphan Diseases
        • 7.3.3.4. Oncology
        • 7.3.3.5. Other
      • 7.3.4. Global Injectable Suspensions Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Injectable Suspensions (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Injectable Suspensions: by End Users(USD Million)
  • Table 2. Injectable Suspensions Hospitals & Clinics , by Region USD Million (2015-2020)
  • Table 3. Injectable Suspensions Home Care Settings , by Region USD Million (2015-2020)
  • Table 4. Injectable Suspensions Other Facilities of Use , by Region USD Million (2015-2020)
  • Table 5. Injectable Suspensions: by Distribution Channel(USD Million)
  • Table 6. Injectable Suspensions Hospitals , by Region USD Million (2015-2020)
  • Table 7. Injectable Suspensions Retail Pharmacy Stores , by Region USD Million (2015-2020)
  • Table 8. Injectable Suspensions: by Therapeutic(USD Million)
  • Table 9. Injectable Suspensions Auto-immune diseases , by Region USD Million (2015-2020)
  • Table 10. Injectable Suspensions Hormonal Disorders , by Region USD Million (2015-2020)
  • Table 11. Injectable Suspensions Orphan Diseases , by Region USD Million (2015-2020)
  • Table 12. Injectable Suspensions Oncology , by Region USD Million (2015-2020)
  • Table 13. Injectable Suspensions Other , by Region USD Million (2015-2020)
  • Table 14. South America Injectable Suspensions, by Country USD Million (2015-2020)
  • Table 15. South America Injectable Suspensions, by End Users USD Million (2015-2020)
  • Table 16. South America Injectable Suspensions, by Distribution Channel USD Million (2015-2020)
  • Table 17. South America Injectable Suspensions, by Therapeutic USD Million (2015-2020)
  • Table 18. Brazil Injectable Suspensions, by End Users USD Million (2015-2020)
  • Table 19. Brazil Injectable Suspensions, by Distribution Channel USD Million (2015-2020)
  • Table 20. Brazil Injectable Suspensions, by Therapeutic USD Million (2015-2020)
  • Table 21. Argentina Injectable Suspensions, by End Users USD Million (2015-2020)
  • Table 22. Argentina Injectable Suspensions, by Distribution Channel USD Million (2015-2020)
  • Table 23. Argentina Injectable Suspensions, by Therapeutic USD Million (2015-2020)
  • Table 24. Rest of South America Injectable Suspensions, by End Users USD Million (2015-2020)
  • Table 25. Rest of South America Injectable Suspensions, by Distribution Channel USD Million (2015-2020)
  • Table 26. Rest of South America Injectable Suspensions, by Therapeutic USD Million (2015-2020)
  • Table 27. Asia Pacific Injectable Suspensions, by Country USD Million (2015-2020)
  • Table 28. Asia Pacific Injectable Suspensions, by End Users USD Million (2015-2020)
  • Table 29. Asia Pacific Injectable Suspensions, by Distribution Channel USD Million (2015-2020)
  • Table 30. Asia Pacific Injectable Suspensions, by Therapeutic USD Million (2015-2020)
  • Table 31. China Injectable Suspensions, by End Users USD Million (2015-2020)
  • Table 32. China Injectable Suspensions, by Distribution Channel USD Million (2015-2020)
  • Table 33. China Injectable Suspensions, by Therapeutic USD Million (2015-2020)
  • Table 34. Japan Injectable Suspensions, by End Users USD Million (2015-2020)
  • Table 35. Japan Injectable Suspensions, by Distribution Channel USD Million (2015-2020)
  • Table 36. Japan Injectable Suspensions, by Therapeutic USD Million (2015-2020)
  • Table 37. India Injectable Suspensions, by End Users USD Million (2015-2020)
  • Table 38. India Injectable Suspensions, by Distribution Channel USD Million (2015-2020)
  • Table 39. India Injectable Suspensions, by Therapeutic USD Million (2015-2020)
  • Table 40. South Korea Injectable Suspensions, by End Users USD Million (2015-2020)
  • Table 41. South Korea Injectable Suspensions, by Distribution Channel USD Million (2015-2020)
  • Table 42. South Korea Injectable Suspensions, by Therapeutic USD Million (2015-2020)
  • Table 43. Taiwan Injectable Suspensions, by End Users USD Million (2015-2020)
  • Table 44. Taiwan Injectable Suspensions, by Distribution Channel USD Million (2015-2020)
  • Table 45. Taiwan Injectable Suspensions, by Therapeutic USD Million (2015-2020)
  • Table 46. Australia Injectable Suspensions, by End Users USD Million (2015-2020)
  • Table 47. Australia Injectable Suspensions, by Distribution Channel USD Million (2015-2020)
  • Table 48. Australia Injectable Suspensions, by Therapeutic USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Injectable Suspensions, by End Users USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Injectable Suspensions, by Distribution Channel USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Injectable Suspensions, by Therapeutic USD Million (2015-2020)
  • Table 52. Europe Injectable Suspensions, by Country USD Million (2015-2020)
  • Table 53. Europe Injectable Suspensions, by End Users USD Million (2015-2020)
  • Table 54. Europe Injectable Suspensions, by Distribution Channel USD Million (2015-2020)
  • Table 55. Europe Injectable Suspensions, by Therapeutic USD Million (2015-2020)
  • Table 56. Germany Injectable Suspensions, by End Users USD Million (2015-2020)
  • Table 57. Germany Injectable Suspensions, by Distribution Channel USD Million (2015-2020)
  • Table 58. Germany Injectable Suspensions, by Therapeutic USD Million (2015-2020)
  • Table 59. France Injectable Suspensions, by End Users USD Million (2015-2020)
  • Table 60. France Injectable Suspensions, by Distribution Channel USD Million (2015-2020)
  • Table 61. France Injectable Suspensions, by Therapeutic USD Million (2015-2020)
  • Table 62. Italy Injectable Suspensions, by End Users USD Million (2015-2020)
  • Table 63. Italy Injectable Suspensions, by Distribution Channel USD Million (2015-2020)
  • Table 64. Italy Injectable Suspensions, by Therapeutic USD Million (2015-2020)
  • Table 65. United Kingdom Injectable Suspensions, by End Users USD Million (2015-2020)
  • Table 66. United Kingdom Injectable Suspensions, by Distribution Channel USD Million (2015-2020)
  • Table 67. United Kingdom Injectable Suspensions, by Therapeutic USD Million (2015-2020)
  • Table 68. Netherlands Injectable Suspensions, by End Users USD Million (2015-2020)
  • Table 69. Netherlands Injectable Suspensions, by Distribution Channel USD Million (2015-2020)
  • Table 70. Netherlands Injectable Suspensions, by Therapeutic USD Million (2015-2020)
  • Table 71. Rest of Europe Injectable Suspensions, by End Users USD Million (2015-2020)
  • Table 72. Rest of Europe Injectable Suspensions, by Distribution Channel USD Million (2015-2020)
  • Table 73. Rest of Europe Injectable Suspensions, by Therapeutic USD Million (2015-2020)
  • Table 74. MEA Injectable Suspensions, by Country USD Million (2015-2020)
  • Table 75. MEA Injectable Suspensions, by End Users USD Million (2015-2020)
  • Table 76. MEA Injectable Suspensions, by Distribution Channel USD Million (2015-2020)
  • Table 77. MEA Injectable Suspensions, by Therapeutic USD Million (2015-2020)
  • Table 78. Middle East Injectable Suspensions, by End Users USD Million (2015-2020)
  • Table 79. Middle East Injectable Suspensions, by Distribution Channel USD Million (2015-2020)
  • Table 80. Middle East Injectable Suspensions, by Therapeutic USD Million (2015-2020)
  • Table 81. Africa Injectable Suspensions, by End Users USD Million (2015-2020)
  • Table 82. Africa Injectable Suspensions, by Distribution Channel USD Million (2015-2020)
  • Table 83. Africa Injectable Suspensions, by Therapeutic USD Million (2015-2020)
  • Table 84. North America Injectable Suspensions, by Country USD Million (2015-2020)
  • Table 85. North America Injectable Suspensions, by End Users USD Million (2015-2020)
  • Table 86. North America Injectable Suspensions, by Distribution Channel USD Million (2015-2020)
  • Table 87. North America Injectable Suspensions, by Therapeutic USD Million (2015-2020)
  • Table 88. United States Injectable Suspensions, by End Users USD Million (2015-2020)
  • Table 89. United States Injectable Suspensions, by Distribution Channel USD Million (2015-2020)
  • Table 90. United States Injectable Suspensions, by Therapeutic USD Million (2015-2020)
  • Table 91. Canada Injectable Suspensions, by End Users USD Million (2015-2020)
  • Table 92. Canada Injectable Suspensions, by Distribution Channel USD Million (2015-2020)
  • Table 93. Canada Injectable Suspensions, by Therapeutic USD Million (2015-2020)
  • Table 94. Mexico Injectable Suspensions, by End Users USD Million (2015-2020)
  • Table 95. Mexico Injectable Suspensions, by Distribution Channel USD Million (2015-2020)
  • Table 96. Mexico Injectable Suspensions, by Therapeutic USD Million (2015-2020)
  • Table 97. Injectable Suspensions Sales: by End Users(K Units)
  • Table 98. Injectable Suspensions Sales Hospitals & Clinics , by Region K Units (2015-2020)
  • Table 99. Injectable Suspensions Sales Home Care Settings , by Region K Units (2015-2020)
  • Table 100. Injectable Suspensions Sales Other Facilities of Use , by Region K Units (2015-2020)
  • Table 101. Injectable Suspensions Sales: by Distribution Channel(K Units)
  • Table 102. Injectable Suspensions Sales Hospitals , by Region K Units (2015-2020)
  • Table 103. Injectable Suspensions Sales Retail Pharmacy Stores , by Region K Units (2015-2020)
  • Table 104. Injectable Suspensions Sales: by Therapeutic(K Units)
  • Table 105. Injectable Suspensions Sales Auto-immune diseases , by Region K Units (2015-2020)
  • Table 106. Injectable Suspensions Sales Hormonal Disorders , by Region K Units (2015-2020)
  • Table 107. Injectable Suspensions Sales Orphan Diseases , by Region K Units (2015-2020)
  • Table 108. Injectable Suspensions Sales Oncology , by Region K Units (2015-2020)
  • Table 109. Injectable Suspensions Sales Other , by Region K Units (2015-2020)
  • Table 110. South America Injectable Suspensions Sales, by Country K Units (2015-2020)
  • Table 111. South America Injectable Suspensions Sales, by End Users K Units (2015-2020)
  • Table 112. South America Injectable Suspensions Sales, by Distribution Channel K Units (2015-2020)
  • Table 113. South America Injectable Suspensions Sales, by Therapeutic K Units (2015-2020)
  • Table 114. Brazil Injectable Suspensions Sales, by End Users K Units (2015-2020)
  • Table 115. Brazil Injectable Suspensions Sales, by Distribution Channel K Units (2015-2020)
  • Table 116. Brazil Injectable Suspensions Sales, by Therapeutic K Units (2015-2020)
  • Table 117. Argentina Injectable Suspensions Sales, by End Users K Units (2015-2020)
  • Table 118. Argentina Injectable Suspensions Sales, by Distribution Channel K Units (2015-2020)
  • Table 119. Argentina Injectable Suspensions Sales, by Therapeutic K Units (2015-2020)
  • Table 120. Rest of South America Injectable Suspensions Sales, by End Users K Units (2015-2020)
  • Table 121. Rest of South America Injectable Suspensions Sales, by Distribution Channel K Units (2015-2020)
  • Table 122. Rest of South America Injectable Suspensions Sales, by Therapeutic K Units (2015-2020)
  • Table 123. Asia Pacific Injectable Suspensions Sales, by Country K Units (2015-2020)
  • Table 124. Asia Pacific Injectable Suspensions Sales, by End Users K Units (2015-2020)
  • Table 125. Asia Pacific Injectable Suspensions Sales, by Distribution Channel K Units (2015-2020)
  • Table 126. Asia Pacific Injectable Suspensions Sales, by Therapeutic K Units (2015-2020)
  • Table 127. China Injectable Suspensions Sales, by End Users K Units (2015-2020)
  • Table 128. China Injectable Suspensions Sales, by Distribution Channel K Units (2015-2020)
  • Table 129. China Injectable Suspensions Sales, by Therapeutic K Units (2015-2020)
  • Table 130. Japan Injectable Suspensions Sales, by End Users K Units (2015-2020)
  • Table 131. Japan Injectable Suspensions Sales, by Distribution Channel K Units (2015-2020)
  • Table 132. Japan Injectable Suspensions Sales, by Therapeutic K Units (2015-2020)
  • Table 133. India Injectable Suspensions Sales, by End Users K Units (2015-2020)
  • Table 134. India Injectable Suspensions Sales, by Distribution Channel K Units (2015-2020)
  • Table 135. India Injectable Suspensions Sales, by Therapeutic K Units (2015-2020)
  • Table 136. South Korea Injectable Suspensions Sales, by End Users K Units (2015-2020)
  • Table 137. South Korea Injectable Suspensions Sales, by Distribution Channel K Units (2015-2020)
  • Table 138. South Korea Injectable Suspensions Sales, by Therapeutic K Units (2015-2020)
  • Table 139. Taiwan Injectable Suspensions Sales, by End Users K Units (2015-2020)
  • Table 140. Taiwan Injectable Suspensions Sales, by Distribution Channel K Units (2015-2020)
  • Table 141. Taiwan Injectable Suspensions Sales, by Therapeutic K Units (2015-2020)
  • Table 142. Australia Injectable Suspensions Sales, by End Users K Units (2015-2020)
  • Table 143. Australia Injectable Suspensions Sales, by Distribution Channel K Units (2015-2020)
  • Table 144. Australia Injectable Suspensions Sales, by Therapeutic K Units (2015-2020)
  • Table 145. Rest of Asia-Pacific Injectable Suspensions Sales, by End Users K Units (2015-2020)
  • Table 146. Rest of Asia-Pacific Injectable Suspensions Sales, by Distribution Channel K Units (2015-2020)
  • Table 147. Rest of Asia-Pacific Injectable Suspensions Sales, by Therapeutic K Units (2015-2020)
  • Table 148. Europe Injectable Suspensions Sales, by Country K Units (2015-2020)
  • Table 149. Europe Injectable Suspensions Sales, by End Users K Units (2015-2020)
  • Table 150. Europe Injectable Suspensions Sales, by Distribution Channel K Units (2015-2020)
  • Table 151. Europe Injectable Suspensions Sales, by Therapeutic K Units (2015-2020)
  • Table 152. Germany Injectable Suspensions Sales, by End Users K Units (2015-2020)
  • Table 153. Germany Injectable Suspensions Sales, by Distribution Channel K Units (2015-2020)
  • Table 154. Germany Injectable Suspensions Sales, by Therapeutic K Units (2015-2020)
  • Table 155. France Injectable Suspensions Sales, by End Users K Units (2015-2020)
  • Table 156. France Injectable Suspensions Sales, by Distribution Channel K Units (2015-2020)
  • Table 157. France Injectable Suspensions Sales, by Therapeutic K Units (2015-2020)
  • Table 158. Italy Injectable Suspensions Sales, by End Users K Units (2015-2020)
  • Table 159. Italy Injectable Suspensions Sales, by Distribution Channel K Units (2015-2020)
  • Table 160. Italy Injectable Suspensions Sales, by Therapeutic K Units (2015-2020)
  • Table 161. United Kingdom Injectable Suspensions Sales, by End Users K Units (2015-2020)
  • Table 162. United Kingdom Injectable Suspensions Sales, by Distribution Channel K Units (2015-2020)
  • Table 163. United Kingdom Injectable Suspensions Sales, by Therapeutic K Units (2015-2020)
  • Table 164. Netherlands Injectable Suspensions Sales, by End Users K Units (2015-2020)
  • Table 165. Netherlands Injectable Suspensions Sales, by Distribution Channel K Units (2015-2020)
  • Table 166. Netherlands Injectable Suspensions Sales, by Therapeutic K Units (2015-2020)
  • Table 167. Rest of Europe Injectable Suspensions Sales, by End Users K Units (2015-2020)
  • Table 168. Rest of Europe Injectable Suspensions Sales, by Distribution Channel K Units (2015-2020)
  • Table 169. Rest of Europe Injectable Suspensions Sales, by Therapeutic K Units (2015-2020)
  • Table 170. MEA Injectable Suspensions Sales, by Country K Units (2015-2020)
  • Table 171. MEA Injectable Suspensions Sales, by End Users K Units (2015-2020)
  • Table 172. MEA Injectable Suspensions Sales, by Distribution Channel K Units (2015-2020)
  • Table 173. MEA Injectable Suspensions Sales, by Therapeutic K Units (2015-2020)
  • Table 174. Middle East Injectable Suspensions Sales, by End Users K Units (2015-2020)
  • Table 175. Middle East Injectable Suspensions Sales, by Distribution Channel K Units (2015-2020)
  • Table 176. Middle East Injectable Suspensions Sales, by Therapeutic K Units (2015-2020)
  • Table 177. Africa Injectable Suspensions Sales, by End Users K Units (2015-2020)
  • Table 178. Africa Injectable Suspensions Sales, by Distribution Channel K Units (2015-2020)
  • Table 179. Africa Injectable Suspensions Sales, by Therapeutic K Units (2015-2020)
  • Table 180. North America Injectable Suspensions Sales, by Country K Units (2015-2020)
  • Table 181. North America Injectable Suspensions Sales, by End Users K Units (2015-2020)
  • Table 182. North America Injectable Suspensions Sales, by Distribution Channel K Units (2015-2020)
  • Table 183. North America Injectable Suspensions Sales, by Therapeutic K Units (2015-2020)
  • Table 184. United States Injectable Suspensions Sales, by End Users K Units (2015-2020)
  • Table 185. United States Injectable Suspensions Sales, by Distribution Channel K Units (2015-2020)
  • Table 186. United States Injectable Suspensions Sales, by Therapeutic K Units (2015-2020)
  • Table 187. Canada Injectable Suspensions Sales, by End Users K Units (2015-2020)
  • Table 188. Canada Injectable Suspensions Sales, by Distribution Channel K Units (2015-2020)
  • Table 189. Canada Injectable Suspensions Sales, by Therapeutic K Units (2015-2020)
  • Table 190. Mexico Injectable Suspensions Sales, by End Users K Units (2015-2020)
  • Table 191. Mexico Injectable Suspensions Sales, by Distribution Channel K Units (2015-2020)
  • Table 192. Mexico Injectable Suspensions Sales, by Therapeutic K Units (2015-2020)
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Injectable Suspensions: by End Users(USD Million)
  • Table 204. Injectable Suspensions Hospitals & Clinics , by Region USD Million (2021-2026)
  • Table 205. Injectable Suspensions Home Care Settings , by Region USD Million (2021-2026)
  • Table 206. Injectable Suspensions Other Facilities of Use , by Region USD Million (2021-2026)
  • Table 207. Injectable Suspensions: by Distribution Channel(USD Million)
  • Table 208. Injectable Suspensions Hospitals , by Region USD Million (2021-2026)
  • Table 209. Injectable Suspensions Retail Pharmacy Stores , by Region USD Million (2021-2026)
  • Table 210. Injectable Suspensions: by Therapeutic(USD Million)
  • Table 211. Injectable Suspensions Auto-immune diseases , by Region USD Million (2021-2026)
  • Table 212. Injectable Suspensions Hormonal Disorders , by Region USD Million (2021-2026)
  • Table 213. Injectable Suspensions Orphan Diseases , by Region USD Million (2021-2026)
  • Table 214. Injectable Suspensions Oncology , by Region USD Million (2021-2026)
  • Table 215. Injectable Suspensions Other , by Region USD Million (2021-2026)
  • Table 216. South America Injectable Suspensions, by Country USD Million (2021-2026)
  • Table 217. South America Injectable Suspensions, by End Users USD Million (2021-2026)
  • Table 218. South America Injectable Suspensions, by Distribution Channel USD Million (2021-2026)
  • Table 219. South America Injectable Suspensions, by Therapeutic USD Million (2021-2026)
  • Table 220. Brazil Injectable Suspensions, by End Users USD Million (2021-2026)
  • Table 221. Brazil Injectable Suspensions, by Distribution Channel USD Million (2021-2026)
  • Table 222. Brazil Injectable Suspensions, by Therapeutic USD Million (2021-2026)
  • Table 223. Argentina Injectable Suspensions, by End Users USD Million (2021-2026)
  • Table 224. Argentina Injectable Suspensions, by Distribution Channel USD Million (2021-2026)
  • Table 225. Argentina Injectable Suspensions, by Therapeutic USD Million (2021-2026)
  • Table 226. Rest of South America Injectable Suspensions, by End Users USD Million (2021-2026)
  • Table 227. Rest of South America Injectable Suspensions, by Distribution Channel USD Million (2021-2026)
  • Table 228. Rest of South America Injectable Suspensions, by Therapeutic USD Million (2021-2026)
  • Table 229. Asia Pacific Injectable Suspensions, by Country USD Million (2021-2026)
  • Table 230. Asia Pacific Injectable Suspensions, by End Users USD Million (2021-2026)
  • Table 231. Asia Pacific Injectable Suspensions, by Distribution Channel USD Million (2021-2026)
  • Table 232. Asia Pacific Injectable Suspensions, by Therapeutic USD Million (2021-2026)
  • Table 233. China Injectable Suspensions, by End Users USD Million (2021-2026)
  • Table 234. China Injectable Suspensions, by Distribution Channel USD Million (2021-2026)
  • Table 235. China Injectable Suspensions, by Therapeutic USD Million (2021-2026)
  • Table 236. Japan Injectable Suspensions, by End Users USD Million (2021-2026)
  • Table 237. Japan Injectable Suspensions, by Distribution Channel USD Million (2021-2026)
  • Table 238. Japan Injectable Suspensions, by Therapeutic USD Million (2021-2026)
  • Table 239. India Injectable Suspensions, by End Users USD Million (2021-2026)
  • Table 240. India Injectable Suspensions, by Distribution Channel USD Million (2021-2026)
  • Table 241. India Injectable Suspensions, by Therapeutic USD Million (2021-2026)
  • Table 242. South Korea Injectable Suspensions, by End Users USD Million (2021-2026)
  • Table 243. South Korea Injectable Suspensions, by Distribution Channel USD Million (2021-2026)
  • Table 244. South Korea Injectable Suspensions, by Therapeutic USD Million (2021-2026)
  • Table 245. Taiwan Injectable Suspensions, by End Users USD Million (2021-2026)
  • Table 246. Taiwan Injectable Suspensions, by Distribution Channel USD Million (2021-2026)
  • Table 247. Taiwan Injectable Suspensions, by Therapeutic USD Million (2021-2026)
  • Table 248. Australia Injectable Suspensions, by End Users USD Million (2021-2026)
  • Table 249. Australia Injectable Suspensions, by Distribution Channel USD Million (2021-2026)
  • Table 250. Australia Injectable Suspensions, by Therapeutic USD Million (2021-2026)
  • Table 251. Rest of Asia-Pacific Injectable Suspensions, by End Users USD Million (2021-2026)
  • Table 252. Rest of Asia-Pacific Injectable Suspensions, by Distribution Channel USD Million (2021-2026)
  • Table 253. Rest of Asia-Pacific Injectable Suspensions, by Therapeutic USD Million (2021-2026)
  • Table 254. Europe Injectable Suspensions, by Country USD Million (2021-2026)
  • Table 255. Europe Injectable Suspensions, by End Users USD Million (2021-2026)
  • Table 256. Europe Injectable Suspensions, by Distribution Channel USD Million (2021-2026)
  • Table 257. Europe Injectable Suspensions, by Therapeutic USD Million (2021-2026)
  • Table 258. Germany Injectable Suspensions, by End Users USD Million (2021-2026)
  • Table 259. Germany Injectable Suspensions, by Distribution Channel USD Million (2021-2026)
  • Table 260. Germany Injectable Suspensions, by Therapeutic USD Million (2021-2026)
  • Table 261. France Injectable Suspensions, by End Users USD Million (2021-2026)
  • Table 262. France Injectable Suspensions, by Distribution Channel USD Million (2021-2026)
  • Table 263. France Injectable Suspensions, by Therapeutic USD Million (2021-2026)
  • Table 264. Italy Injectable Suspensions, by End Users USD Million (2021-2026)
  • Table 265. Italy Injectable Suspensions, by Distribution Channel USD Million (2021-2026)
  • Table 266. Italy Injectable Suspensions, by Therapeutic USD Million (2021-2026)
  • Table 267. United Kingdom Injectable Suspensions, by End Users USD Million (2021-2026)
  • Table 268. United Kingdom Injectable Suspensions, by Distribution Channel USD Million (2021-2026)
  • Table 269. United Kingdom Injectable Suspensions, by Therapeutic USD Million (2021-2026)
  • Table 270. Netherlands Injectable Suspensions, by End Users USD Million (2021-2026)
  • Table 271. Netherlands Injectable Suspensions, by Distribution Channel USD Million (2021-2026)
  • Table 272. Netherlands Injectable Suspensions, by Therapeutic USD Million (2021-2026)
  • Table 273. Rest of Europe Injectable Suspensions, by End Users USD Million (2021-2026)
  • Table 274. Rest of Europe Injectable Suspensions, by Distribution Channel USD Million (2021-2026)
  • Table 275. Rest of Europe Injectable Suspensions, by Therapeutic USD Million (2021-2026)
  • Table 276. MEA Injectable Suspensions, by Country USD Million (2021-2026)
  • Table 277. MEA Injectable Suspensions, by End Users USD Million (2021-2026)
  • Table 278. MEA Injectable Suspensions, by Distribution Channel USD Million (2021-2026)
  • Table 279. MEA Injectable Suspensions, by Therapeutic USD Million (2021-2026)
  • Table 280. Middle East Injectable Suspensions, by End Users USD Million (2021-2026)
  • Table 281. Middle East Injectable Suspensions, by Distribution Channel USD Million (2021-2026)
  • Table 282. Middle East Injectable Suspensions, by Therapeutic USD Million (2021-2026)
  • Table 283. Africa Injectable Suspensions, by End Users USD Million (2021-2026)
  • Table 284. Africa Injectable Suspensions, by Distribution Channel USD Million (2021-2026)
  • Table 285. Africa Injectable Suspensions, by Therapeutic USD Million (2021-2026)
  • Table 286. North America Injectable Suspensions, by Country USD Million (2021-2026)
  • Table 287. North America Injectable Suspensions, by End Users USD Million (2021-2026)
  • Table 288. North America Injectable Suspensions, by Distribution Channel USD Million (2021-2026)
  • Table 289. North America Injectable Suspensions, by Therapeutic USD Million (2021-2026)
  • Table 290. United States Injectable Suspensions, by End Users USD Million (2021-2026)
  • Table 291. United States Injectable Suspensions, by Distribution Channel USD Million (2021-2026)
  • Table 292. United States Injectable Suspensions, by Therapeutic USD Million (2021-2026)
  • Table 293. Canada Injectable Suspensions, by End Users USD Million (2021-2026)
  • Table 294. Canada Injectable Suspensions, by Distribution Channel USD Million (2021-2026)
  • Table 295. Canada Injectable Suspensions, by Therapeutic USD Million (2021-2026)
  • Table 296. Mexico Injectable Suspensions, by End Users USD Million (2021-2026)
  • Table 297. Mexico Injectable Suspensions, by Distribution Channel USD Million (2021-2026)
  • Table 298. Mexico Injectable Suspensions, by Therapeutic USD Million (2021-2026)
  • Table 299. Injectable Suspensions Sales: by End Users(K Units)
  • Table 300. Injectable Suspensions Sales Hospitals & Clinics , by Region K Units (2021-2026)
  • Table 301. Injectable Suspensions Sales Home Care Settings , by Region K Units (2021-2026)
  • Table 302. Injectable Suspensions Sales Other Facilities of Use , by Region K Units (2021-2026)
  • Table 303. Injectable Suspensions Sales: by Distribution Channel(K Units)
  • Table 304. Injectable Suspensions Sales Hospitals , by Region K Units (2021-2026)
  • Table 305. Injectable Suspensions Sales Retail Pharmacy Stores , by Region K Units (2021-2026)
  • Table 306. Injectable Suspensions Sales: by Therapeutic(K Units)
  • Table 307. Injectable Suspensions Sales Auto-immune diseases , by Region K Units (2021-2026)
  • Table 308. Injectable Suspensions Sales Hormonal Disorders , by Region K Units (2021-2026)
  • Table 309. Injectable Suspensions Sales Orphan Diseases , by Region K Units (2021-2026)
  • Table 310. Injectable Suspensions Sales Oncology , by Region K Units (2021-2026)
  • Table 311. Injectable Suspensions Sales Other , by Region K Units (2021-2026)
  • Table 312. South America Injectable Suspensions Sales, by Country K Units (2021-2026)
  • Table 313. South America Injectable Suspensions Sales, by End Users K Units (2021-2026)
  • Table 314. South America Injectable Suspensions Sales, by Distribution Channel K Units (2021-2026)
  • Table 315. South America Injectable Suspensions Sales, by Therapeutic K Units (2021-2026)
  • Table 316. Brazil Injectable Suspensions Sales, by End Users K Units (2021-2026)
  • Table 317. Brazil Injectable Suspensions Sales, by Distribution Channel K Units (2021-2026)
  • Table 318. Brazil Injectable Suspensions Sales, by Therapeutic K Units (2021-2026)
  • Table 319. Argentina Injectable Suspensions Sales, by End Users K Units (2021-2026)
  • Table 320. Argentina Injectable Suspensions Sales, by Distribution Channel K Units (2021-2026)
  • Table 321. Argentina Injectable Suspensions Sales, by Therapeutic K Units (2021-2026)
  • Table 322. Rest of South America Injectable Suspensions Sales, by End Users K Units (2021-2026)
  • Table 323. Rest of South America Injectable Suspensions Sales, by Distribution Channel K Units (2021-2026)
  • Table 324. Rest of South America Injectable Suspensions Sales, by Therapeutic K Units (2021-2026)
  • Table 325. Asia Pacific Injectable Suspensions Sales, by Country K Units (2021-2026)
  • Table 326. Asia Pacific Injectable Suspensions Sales, by End Users K Units (2021-2026)
  • Table 327. Asia Pacific Injectable Suspensions Sales, by Distribution Channel K Units (2021-2026)
  • Table 328. Asia Pacific Injectable Suspensions Sales, by Therapeutic K Units (2021-2026)
  • Table 329. China Injectable Suspensions Sales, by End Users K Units (2021-2026)
  • Table 330. China Injectable Suspensions Sales, by Distribution Channel K Units (2021-2026)
  • Table 331. China Injectable Suspensions Sales, by Therapeutic K Units (2021-2026)
  • Table 332. Japan Injectable Suspensions Sales, by End Users K Units (2021-2026)
  • Table 333. Japan Injectable Suspensions Sales, by Distribution Channel K Units (2021-2026)
  • Table 334. Japan Injectable Suspensions Sales, by Therapeutic K Units (2021-2026)
  • Table 335. India Injectable Suspensions Sales, by End Users K Units (2021-2026)
  • Table 336. India Injectable Suspensions Sales, by Distribution Channel K Units (2021-2026)
  • Table 337. India Injectable Suspensions Sales, by Therapeutic K Units (2021-2026)
  • Table 338. South Korea Injectable Suspensions Sales, by End Users K Units (2021-2026)
  • Table 339. South Korea Injectable Suspensions Sales, by Distribution Channel K Units (2021-2026)
  • Table 340. South Korea Injectable Suspensions Sales, by Therapeutic K Units (2021-2026)
  • Table 341. Taiwan Injectable Suspensions Sales, by End Users K Units (2021-2026)
  • Table 342. Taiwan Injectable Suspensions Sales, by Distribution Channel K Units (2021-2026)
  • Table 343. Taiwan Injectable Suspensions Sales, by Therapeutic K Units (2021-2026)
  • Table 344. Australia Injectable Suspensions Sales, by End Users K Units (2021-2026)
  • Table 345. Australia Injectable Suspensions Sales, by Distribution Channel K Units (2021-2026)
  • Table 346. Australia Injectable Suspensions Sales, by Therapeutic K Units (2021-2026)
  • Table 347. Rest of Asia-Pacific Injectable Suspensions Sales, by End Users K Units (2021-2026)
  • Table 348. Rest of Asia-Pacific Injectable Suspensions Sales, by Distribution Channel K Units (2021-2026)
  • Table 349. Rest of Asia-Pacific Injectable Suspensions Sales, by Therapeutic K Units (2021-2026)
  • Table 350. Europe Injectable Suspensions Sales, by Country K Units (2021-2026)
  • Table 351. Europe Injectable Suspensions Sales, by End Users K Units (2021-2026)
  • Table 352. Europe Injectable Suspensions Sales, by Distribution Channel K Units (2021-2026)
  • Table 353. Europe Injectable Suspensions Sales, by Therapeutic K Units (2021-2026)
  • Table 354. Germany Injectable Suspensions Sales, by End Users K Units (2021-2026)
  • Table 355. Germany Injectable Suspensions Sales, by Distribution Channel K Units (2021-2026)
  • Table 356. Germany Injectable Suspensions Sales, by Therapeutic K Units (2021-2026)
  • Table 357. France Injectable Suspensions Sales, by End Users K Units (2021-2026)
  • Table 358. France Injectable Suspensions Sales, by Distribution Channel K Units (2021-2026)
  • Table 359. France Injectable Suspensions Sales, by Therapeutic K Units (2021-2026)
  • Table 360. Italy Injectable Suspensions Sales, by End Users K Units (2021-2026)
  • Table 361. Italy Injectable Suspensions Sales, by Distribution Channel K Units (2021-2026)
  • Table 362. Italy Injectable Suspensions Sales, by Therapeutic K Units (2021-2026)
  • Table 363. United Kingdom Injectable Suspensions Sales, by End Users K Units (2021-2026)
  • Table 364. United Kingdom Injectable Suspensions Sales, by Distribution Channel K Units (2021-2026)
  • Table 365. United Kingdom Injectable Suspensions Sales, by Therapeutic K Units (2021-2026)
  • Table 366. Netherlands Injectable Suspensions Sales, by End Users K Units (2021-2026)
  • Table 367. Netherlands Injectable Suspensions Sales, by Distribution Channel K Units (2021-2026)
  • Table 368. Netherlands Injectable Suspensions Sales, by Therapeutic K Units (2021-2026)
  • Table 369. Rest of Europe Injectable Suspensions Sales, by End Users K Units (2021-2026)
  • Table 370. Rest of Europe Injectable Suspensions Sales, by Distribution Channel K Units (2021-2026)
  • Table 371. Rest of Europe Injectable Suspensions Sales, by Therapeutic K Units (2021-2026)
  • Table 372. MEA Injectable Suspensions Sales, by Country K Units (2021-2026)
  • Table 373. MEA Injectable Suspensions Sales, by End Users K Units (2021-2026)
  • Table 374. MEA Injectable Suspensions Sales, by Distribution Channel K Units (2021-2026)
  • Table 375. MEA Injectable Suspensions Sales, by Therapeutic K Units (2021-2026)
  • Table 376. Middle East Injectable Suspensions Sales, by End Users K Units (2021-2026)
  • Table 377. Middle East Injectable Suspensions Sales, by Distribution Channel K Units (2021-2026)
  • Table 378. Middle East Injectable Suspensions Sales, by Therapeutic K Units (2021-2026)
  • Table 379. Africa Injectable Suspensions Sales, by End Users K Units (2021-2026)
  • Table 380. Africa Injectable Suspensions Sales, by Distribution Channel K Units (2021-2026)
  • Table 381. Africa Injectable Suspensions Sales, by Therapeutic K Units (2021-2026)
  • Table 382. North America Injectable Suspensions Sales, by Country K Units (2021-2026)
  • Table 383. North America Injectable Suspensions Sales, by End Users K Units (2021-2026)
  • Table 384. North America Injectable Suspensions Sales, by Distribution Channel K Units (2021-2026)
  • Table 385. North America Injectable Suspensions Sales, by Therapeutic K Units (2021-2026)
  • Table 386. United States Injectable Suspensions Sales, by End Users K Units (2021-2026)
  • Table 387. United States Injectable Suspensions Sales, by Distribution Channel K Units (2021-2026)
  • Table 388. United States Injectable Suspensions Sales, by Therapeutic K Units (2021-2026)
  • Table 389. Canada Injectable Suspensions Sales, by End Users K Units (2021-2026)
  • Table 390. Canada Injectable Suspensions Sales, by Distribution Channel K Units (2021-2026)
  • Table 391. Canada Injectable Suspensions Sales, by Therapeutic K Units (2021-2026)
  • Table 392. Mexico Injectable Suspensions Sales, by End Users K Units (2021-2026)
  • Table 393. Mexico Injectable Suspensions Sales, by Distribution Channel K Units (2021-2026)
  • Table 394. Mexico Injectable Suspensions Sales, by Therapeutic K Units (2021-2026)
  • Table 395. Research Programs/Design for This Report
  • Table 396. Key Data Information from Secondary Sources
  • Table 397. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Injectable Suspensions: by End Users USD Million (2015-2020)
  • Figure 5. Global Injectable Suspensions: by Distribution Channel USD Million (2015-2020)
  • Figure 6. Global Injectable Suspensions: by Therapeutic USD Million (2015-2020)
  • Figure 7. South America Injectable Suspensions Share (%), by Country
  • Figure 8. Asia Pacific Injectable Suspensions Share (%), by Country
  • Figure 9. Europe Injectable Suspensions Share (%), by Country
  • Figure 10. MEA Injectable Suspensions Share (%), by Country
  • Figure 11. North America Injectable Suspensions Share (%), by Country
  • Figure 12. Global Injectable Suspensions: by End Users K Units (2015-2020)
  • Figure 13. Global Injectable Suspensions: by Distribution Channel K Units (2015-2020)
  • Figure 14. Global Injectable Suspensions: by Therapeutic K Units (2015-2020)
  • Figure 15. South America Injectable Suspensions Share (%), by Country
  • Figure 16. Asia Pacific Injectable Suspensions Share (%), by Country
  • Figure 17. Europe Injectable Suspensions Share (%), by Country
  • Figure 18. MEA Injectable Suspensions Share (%), by Country
  • Figure 19. North America Injectable Suspensions Share (%), by Country
  • Figure 20. Global Injectable Suspensions share by Players 2020 (%)
  • Figure 21. Global Injectable Suspensions share by Players (Top 3) 2020(%)
  • Figure 22. Global Injectable Suspensions share by Players (Top 5) 2020(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 26. Teva (Israel) Revenue, Net Income and Gross profit
  • Figure 27. Teva (Israel) Revenue: by Geography 2020
  • Figure 28. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 29. Mylan (United States) Revenue: by Geography 2020
  • Figure 30. Sandoz (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. Sandoz (Switzerland) Revenue: by Geography 2020
  • Figure 32. Cosmo Pharmaceuticals (Ireland) Revenue, Net Income and Gross profit
  • Figure 33. Cosmo Pharmaceuticals (Ireland) Revenue: by Geography 2020
  • Figure 34. Salix (United States) Revenue, Net Income and Gross profit
  • Figure 35. Salix (United States) Revenue: by Geography 2020
  • Figure 36. Chiesi Farmaceutici (Italy) Revenue, Net Income and Gross profit
  • Figure 37. Chiesi Farmaceutici (Italy) Revenue: by Geography 2020
  • Figure 38. Orion Corporation (Finland) Revenue, Net Income and Gross profit
  • Figure 39. Orion Corporation (Finland) Revenue: by Geography 2020
  • Figure 40. Cipla (India) Revenue, Net Income and Gross profit
  • Figure 41. Cipla (India) Revenue: by Geography 2020
  • Figure 42. Synmosa Biopharma (Taiwan) Revenue, Net Income and Gross profit
  • Figure 43. Synmosa Biopharma (Taiwan) Revenue: by Geography 2020
  • Figure 44. Global Injectable Suspensions: by End Users USD Million (2021-2026)
  • Figure 45. Global Injectable Suspensions: by Distribution Channel USD Million (2021-2026)
  • Figure 46. Global Injectable Suspensions: by Therapeutic USD Million (2021-2026)
  • Figure 47. South America Injectable Suspensions Share (%), by Country
  • Figure 48. Asia Pacific Injectable Suspensions Share (%), by Country
  • Figure 49. Europe Injectable Suspensions Share (%), by Country
  • Figure 50. MEA Injectable Suspensions Share (%), by Country
  • Figure 51. North America Injectable Suspensions Share (%), by Country
  • Figure 52. Global Injectable Suspensions: by End Users K Units (2021-2026)
  • Figure 53. Global Injectable Suspensions: by Distribution Channel K Units (2021-2026)
  • Figure 54. Global Injectable Suspensions: by Therapeutic K Units (2021-2026)
  • Figure 55. South America Injectable Suspensions Share (%), by Country
  • Figure 56. Asia Pacific Injectable Suspensions Share (%), by Country
  • Figure 57. Europe Injectable Suspensions Share (%), by Country
  • Figure 58. MEA Injectable Suspensions Share (%), by Country
  • Figure 59. North America Injectable Suspensions Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • AstraZeneca (United Kingdom)
  • Teva (Israel)
  • Mylan (United States)
  • Sandoz (Switzerland)
  • Cosmo Pharmaceuticals (Ireland)
  • Salix (United States)
  • Chiesi Farmaceutici (Italy)
  • Orion Corporation (Finland)
  • Cipla (India)
  • Synmosa Biopharma (Taiwan)
Additional players considered in the study are as follows:
Lunan Better Pharma (United States) , Shanghai Sine Promod (China)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation